Aldeyra Therapeutics Faces Class Action Lawsuits
Analysis based on 74 articles · First reported Apr 01, 2026 · Last updated Apr 30, 2026
The class action lawsuits against Aldeyra Therapeutics could negatively impact its stock price and investor confidence due to allegations of misleading statements regarding drug trial results. This event highlights the risks associated with investing in biotechnology companies and the importance of transparent reporting of clinical trial data.
Multiple investor-rights law firms, including Bronstein, Gewirtz & Grossman, LLC and Rosen Law Firm, have filed class action lawsuits against Aldeyra Therapeutics. The lawsuits allege that Aldeyra Therapeutics and its officers made false and misleading statements and/or failed to disclose that the results of its reproxalap drug candidate's clinical trials were inconsistent and unreliable. The class period for affected investors is between November 3, 2023, and March 16, 2026. Investors who suffered losses are encouraged to join the lawsuits, with a lead plaintiff deadline of May 29, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard